Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Dynamic trajectories of electrolytes and bone metabolism with tofogliflozin and glimepiride: A post-hoc analysis.

Created on 13 Nov 2026

Authors

Shota Tokuno, Yumie Takeshita, Daiki Matsubara, Chiaki Nomura, Miki Okumura, Yujiro Nakano, Taro Yamashita, Masao Honda, Toshinari Takamura

Published in

Journal of pharmacological sciences. Volume 162. Issue 4. Pages 319-330. Epub Oct 15, 2026.

Abstract

Sodium-glucose cotransporter 2 (SGLT2) inhibitors influence electrolyte balance and bone metabolism. However, their effects in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and type 2 diabetes remain unclear.
40 participants with type 2 diabetes and MASLD were randomly assigned to tofogliflozin (20 mg/day) or glimepiride (0.5-6.0 mg/day) for 48 weeks. Changes in anthropometric measures, electrolytes, and bone metabolism markers were evaluated.
Tofogliflozin significantly increased serum magnesium (2.0 ± 0.19 to 2.13 ± 0.18 mg/dL) and transiently elevated serum calcium (9.15 to a maximum of 9.60 mg/dL) and tartrate-resistant acid phosphatase 5 b (283.5 to 352.0 mU/dL). It also transiently reduced serum potassium (4.05 ± 0.31 to 3.89 ± 0.21 mEq/L) and uric acid (5.10 to a minimum of 4.55 mg/dL), accompanied by increased urinary potassium excretion and fractional uric acid excretion. Urinary magnesium and calcium excretion did not change significantly. In the tofogliflozin group, reductions in steatosis and hepatocellular ballooning scores were significantly correlated with increases in serum type I collagen cross-linked N-telopeptide.
Tofogliflozin modified electrolyte profiles and transiently influenced bone turnover markers. The observed correlations suggest a potential association between improvements in hepatic histology and changes in bone metabolism during SGLT2 inhibitor therapy.

PMID:
43020535
Bibliographic data and abstract were imported from PubMed on 13 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 6
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement